aap Implantate’s recent results for Q317 and the first nine months of 2017 (9M17) justified its recent trauma focus with 11% and 13% increases in trauma sales, respectively. With investments in the Quality First initiative, the evaluation of strategic options and the share buyback, it was pleasing to see that sales and EBITDA (loss) continue to be expected within the guidance range for the full year, albeit towards the lower end of the range.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs